Innocan Pharma Announces First Tranche Closing of Private Placement of Units
Why now
Thesis: Micro-cap financing, negligible market impact
Catalyst to watch: Use of proceeds or further tranches
Main risk: Dilution pressures share price
Why it matters
Small private placement funds a micro-cap; dilution and financing news with no index-level relevance.
Details
HERZLIYA, Israel and CALGARY, Alberta, Sept. 23, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTC: INNPF) (the "Company" or "Innocan") is pleased to announce that, further to its press release of September 9, 2026, it has complete a private placement of 247,314...
Related assets & topics
HealthcareSources
- prnewswire · 2026-09-23 20:01 UTC